{"entity":{"id":"gefitinib-chemo-tmh","kind":"trial","name":"Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)","aka":[],"tldr":"An Indian trial showed that adding standard chemotherapy to the cheap first-generation pill gefitinib doubled the time lung cancer stayed controlled and cut deaths by more than half.","summary":"350 patients were randomised (176 gefitinib, 174 gefitinib plus pemetrexed-carboplatin). Median progression-free survival was 16 months with the combination versus 8 months with gefitinib alone (hazard ratio for progression or death 0.51; P<0.001); median overall survival was not reached versus 17 months (hazard ratio for death 0.45; P<0.001); response rates were 75% versus 63%, at the cost of more grade 3 or worse toxicity (51% versus 25%). With the Japanese NEJ009 trial it established EGFR inhibitor plus chemotherapy as an option, and offered a low-cost alternative where osimertinib is unaffordable; the approach later re-emerged in FLAURA2.","status":"positive","asOf":"2026-09-10","links":[{"label":"Noronha et al., JCO 2020","url":"https://doi.org/10.1200/JCO.19.01154"}],"tags":[],"related":[],"cancers":["nsclc","egfr-mutant-nsclc"],"sections":[],"technologies":["kinase-inhibitors","cytotoxic-chemotherapy"],"targets":["egfr"],"drugs":["gefitinib","pemetrexed","carboplatin"],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":["pfs"],"trials":[],"people":["noronha-vanita","prabhash-kumar"],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":["paper-noronha-j-clin-oncol"],"journals":[],"dependsOn":[],"notes":[],"phase":"3","setting":"Untreated advanced EGFR-mutant non-small-cell lung cancer: gefitinib alone vs gefitinib plus pemetrexed and carboplatin","sponsor":"Tata Memorial Centre","result":"PFS 16 vs 8 months (HR 0.51); OS not reached vs 17 months (HR 0.45).","yearReported":2020,"enrolled":350,"enrolledBasis":"registry","outcomes":[{"endpoint":"Median progression-free survival","primary":true,"unit":"months","arms":[{"name":"Gefitinib + pemetrexed-carboplatin","n":174,"value":16},{"name":"Gefitinib","n":176,"value":8}],"hr":0.51,"p":"<0.001","source":"https://doi.org/10.1200/JCO.19.01154"}]},"route":"/trials/gefitinib-chemo-tmh/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"institution":[{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/"}],"term":[{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/"}],"person":[{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/"},{"id":"noronha-vanita","kind":"person","name":"Vanita Noronha","route":"/people/noronha-vanita/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"paper":[{"id":"paper-noronha-j-clin-oncol","kind":"paper","name":"Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer","route":"/key-papers/paper-noronha-j-clin-oncol/"}],"roadmap":[{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/"}]}}